Generated by AI
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.
Website5858 Horton Street
EmeryVille, CA, 94608
United States
The latest articles about FDMT.
Summary of Aug 17's posts. Generated by AI.
Summary of Aug 5's posts. Generated by AI.
Summary of Feb 6's posts. Generated by AI.
Investors talking about FDMT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.